the corporate presentation ennaid therapeutics
DESCRIPTION
TRANSCRIPT
Curing Infectious DiseasesSept.,2013
Our First Target is Dengue Fever
1
400 Million Dengue Infections Annually
2CDC-HeathMap Collaboration, http://www.healthmap.org/dengue/index.php
We Have A Cure For Dengue
3
Control Neutralizing Serum
A Control
Peptide 57
B Control
Peptide ETX-101
C
>99% Inhibition
ETX-101 Mechanism of Action
4
Issued, Filed or Pending Patents
5
Dengue Products In Development
6
Our Expert Team
7
Robert F. Garry, Ph.D.Inventor – 30 YrsChief Science Officer
Elizabeth Moore, RPh30 Yrs Experience Gov’t/IndustryRegulatory Affairs
Darnisha HarrisonMicrobiologist/Bus. Dev Licensing – 19yrsPresident & CEO
Scott Michael, Ph.D.Co-inventor – 15 YrsScientific Advisor
SUPPORT TEAM
Adrian Barfied23 YrsPharma EntrepreneurRomeo Ibrahim20 YrsProcess ScientistThandeka Myeni, MD14 YrsMedical AdvisorGeorge Davis20 YrsCorporate Affairs
TIBA OncologyP4 Healthcare
Dengue Therapeutic Development Plan
8
Preclinical Preparation
EffectivenessNon-Human
Primates
Pre-IND Meeting
Safety/Toxicity Non-Human
PrimatesIND
SubmissionPhase I/IIa
Clinical TrialPhase I/IIa Data
Retrieval & Publishing
July 2013 Jan 2014 May 2014 Mar 2015 July 2015 May 2016 Oct 2016
$35K $3.7M $265K $3.75M $250K $11M $1M
$4,000,000 $4,000,000 $12,000,000
Market Potential
9
$63 Per Dose
$0
$500
$1,000
$1,500
$2,000
Year 1 Year 2 Year 3 Year 4 Year 5
$1.69 Billion
40%
40%
40%
40%
40%
Economic Savings
Revenue In Millions
Monetization/Exit Strategies
10
Dengue Is Just The Beginning
11
West Nile Virus Hepatitis C
30M Annual Infections 170M Annual Infections
200M Additional Doses
Thank YouI Trust That I Have Thoroughly Convinced You That Ennaid Has The Solution, The Plan & The Team To Develop Cures For All Four Strains Of Dengue Virus, Followed by Hepatitis C Virus & West Nile Virus.